Cover Image

Chimeric antigen receptor (CAR) T-cell therapy in hematologic malignancies: clinical implications and limitations

Chimeric antigen receptor (CAR) T-cell therapy has become a powerful treatment option in B-cell and plasma cell malignancies, and many patients have benefited from its use. To date, six CAR T-cell products have been approved by the FDA and EMA, and many more are being developed and investigated in c...

Full description

Saved in:
Bibliographic Details
Main Authors: Blüm, Philipp (Author) , Kayser, Sabine (Author)
Format: Article (Journal)
Language:English
Published: 22 April 2024
In: Cancers
Year: 2024, Volume: 16, Issue: 8, Pages: 1-29
ISSN:2072-6694
DOI:10.3390/cancers16081599
Online Access:Verlag, kostenfrei, Volltext: https://doi.org/10.3390/cancers16081599
Verlag, kostenfrei, Volltext: https://www.mdpi.com/2072-6694/16/8/1599
Get full text
Author Notes:Philipp Blüm and Sabine Kayser

MARC

LEADER 00000caa a2200000 c 4500
001 1905723857
003 DE-627
005 20241205181211.0
007 cr uuu---uuuuu
008 241015s2024 xx |||||o 00| ||eng c
024 7 |a 10.3390/cancers16081599  |2 doi 
035 |a (DE-627)1905723857 
035 |a (DE-599)KXP1905723857 
035 |a (OCoLC)1475315793 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 33  |2 sdnb 
100 1 |a Blüm, Philipp  |e VerfasserIn  |0 (DE-588)1344991505  |0 (DE-627)1905725485  |4 aut 
245 1 0 |a Chimeric antigen receptor (CAR) T-cell therapy in hematologic malignancies  |b clinical implications and limitations  |c Philipp Blüm and Sabine Kayser 
246 1 |i Titel des special issue  |a Innovative Immunotherapies: CAR-T Cell Therapy for Cancers 
264 1 |c 22 April 2024 
300 |b Illustrationen 
300 |a 29 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
500 |a Gesehen am 15.10.2024 
520 |a Chimeric antigen receptor (CAR) T-cell therapy has become a powerful treatment option in B-cell and plasma cell malignancies, and many patients have benefited from its use. To date, six CAR T-cell products have been approved by the FDA and EMA, and many more are being developed and investigated in clinical trials. The whole field of adoptive cell transfer has experienced an unbelievable development process, and we are now at the edge of a new era of immune therapies that will have its impact beyond hematologic malignancies. Areas of interest are, e.g., solid oncology, autoimmune diseases, infectious diseases, and others. Although much has been achieved so far, there is still a huge effort needed to overcome significant challenges and difficulties. We are witnessing a rapid expansion of knowledge, induced by new biomedical technologies and CAR designs. The era of CAR T-cell therapy has just begun, and new products will widen the therapeutic landscape in the future. This review provides a comprehensive overview of the clinical applications of CAR T-cells, focusing on the approved products and emphasizing their benefits but also indicating limitations and challenges. 
650 4 |a axicabtagene ciloleucel 
650 4 |a brexucabtagene autoleucel 
650 4 |a CAR T-cells 
650 4 |a chimeric antigen receptor T-cells 
650 4 |a ciltacabtagene autoleucel 
650 4 |a cytokine release syndrome 
650 4 |a idecabtagene vicleucel 
650 4 |a immune effector cell-associated neurotoxicity syndrome 
650 4 |a lisocabtagene maraleucel 
650 4 |a tisagenlecleucel 
700 1 |a Kayser, Sabine  |d 1979-  |e VerfasserIn  |0 (DE-588)138694923  |0 (DE-627)605256233  |0 (DE-576)30778813X  |4 aut 
773 0 8 |i Enthalten in  |t Cancers  |d Basel : MDPI, 2009  |g 16(2024), 8, special issue, Artikel-ID 1599, Seite 1-29  |h Online-Ressource  |w (DE-627)614095670  |w (DE-600)2527080-1  |w (DE-576)313958548  |x 2072-6694  |7 nnas  |a Chimeric antigen receptor (CAR) T-cell therapy in hematologic malignancies clinical implications and limitations 
773 1 8 |g volume:16  |g year:2024  |g number:8  |g supplement:special issue  |g elocationid:1599  |g pages:1-29  |g extent:29  |a Chimeric antigen receptor (CAR) T-cell therapy in hematologic malignancies clinical implications and limitations 
856 4 0 |u https://doi.org/10.3390/cancers16081599  |x Verlag  |x Resolving-System  |z kostenfrei  |3 Volltext 
856 4 0 |u https://www.mdpi.com/2072-6694/16/8/1599  |x Verlag  |z kostenfrei  |3 Volltext 
951 |a AR 
992 |a 20241015 
993 |a Article 
994 |a 2024 
998 |g 138694923  |a Kayser, Sabine  |m 138694923:Kayser, Sabine  |d 60000  |d 63500  |e 60000PK138694923  |e 63500PK138694923  |k 0/60000/  |k 1/60000/63500/  |p 2  |y j 
998 |g 1344991505  |a Blüm, Philipp  |m 1344991505:Blüm, Philipp  |d 60000  |d 63500  |e 60000PB1344991505  |e 63500PB1344991505  |k 0/60000/  |k 1/60000/63500/  |p 1  |x j 
999 |a KXP-PPN1905723857  |e 4595443838 
BIB |a Y 
SER |a journal 
JSO |a {"id":{"doi":["10.3390/cancers16081599"],"eki":["1905723857"]},"type":{"bibl":"article-journal","media":"Online-Ressource"},"physDesc":[{"noteIll":"Illustrationen","extent":"29 S."}],"note":["Gesehen am 15.10.2024"],"relHost":[{"type":{"bibl":"periodical","media":"Online-Ressource"},"pubHistory":["1.2009 -"],"disp":"Chimeric antigen receptor (CAR) T-cell therapy in hematologic malignancies clinical implications and limitationsCancers","recId":"614095670","language":["eng"],"physDesc":[{"extent":"Online-Ressource"}],"part":{"issue":"8","extent":"29","pages":"1-29","year":"2024","text":"16(2024), 8, special issue, Artikel-ID 1599, Seite 1-29","volume":"16"},"id":{"zdb":["2527080-1"],"issn":["2072-6694"],"eki":["614095670"]},"note":["Gesehen am 27.05.2020"],"origin":[{"publisher":"MDPI","dateIssuedDisp":"2009-","dateIssuedKey":"2009","publisherPlace":"Basel"}],"name":{"displayForm":["Molecular Diversity Preservation International (MDPI)"]},"title":[{"title_sort":"Cancers","title":"Cancers"}]}],"origin":[{"dateIssuedDisp":"22 April 2024","dateIssuedKey":"2024"}],"name":{"displayForm":["Philipp Blüm and Sabine Kayser"]},"recId":"1905723857","person":[{"role":"aut","family":"Blüm","display":"Blüm, Philipp","given":"Philipp"},{"role":"aut","family":"Kayser","display":"Kayser, Sabine","given":"Sabine"}],"titleAlt":[{"title":"Innovative Immunotherapies: CAR-T Cell Therapy for Cancers"}],"title":[{"title_sort":"Chimeric antigen receptor (CAR) T-cell therapy in hematologic malignancies","subtitle":"clinical implications and limitations","title":"Chimeric antigen receptor (CAR) T-cell therapy in hematologic malignancies"}],"language":["eng"]} 
SRT |a BLUEMPHILICHIMERICAN2220 

Similar Items